Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3800
Dr. Rosenbluth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2013
Vanderbilt University School of MedicineClass of 2011
Certifications & Licensure
CA State Medical License 2021 - 2025
MA State Medical License 2014 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, Christopher J Schwartz, Hidetoshi Mori
JAMA Oncology. 2025-03-01 - 4 citationsImplantation of engineered adipocytes suppresses tumor progression in cancer models.Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng
Nature Biotechnology. 2025-02-04 - 2 citationsT Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.Nam Woo Cho, Sophia M Guldberg, Barzin Y Nabet, Jie Zeng Yu, Eun Ji Kim
Cancer Immunology Research. 2025-02-03
Press Mentions
Experimental Treatment Uses Engineered Fat Cells to “Starve” TumorsMarch 27th, 2025- CRISPR Transforms Ordinary Fat Cells into Cancer Killing MachinesFebruary 25th, 2025
- Engineered Adipocytes Target Tumor Growth in Cancer ModelsFebruary 6th, 2025
- Join now to see all
Grant Support
- Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cellsUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
